



ABN 53 075 582 740

ASX ANNOUNCEMENT

15 November 2017

Bionomics Limited (ASX:BNO, OTCQX: BNOEF) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all resolutions considered before the Annual General Meeting today.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 13 October 2017.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Result	Proxy Votes			
			For	Against	Abstain	Proxy's discretion
1	Adoption of Remuneration Report	Carried unanimously on a show of hands	136,205,223	9,918,930	313,733	907,924
2	Re-election of Non-Executive Director – Mr Peter Turner	Carried unanimously on a show of hands	145,301,899	508,414	599,338	936,159
3.	Approval of Proposed Issue of Share Options to Dr Deborah Rathjen	Carried unanimously on a show of hands	135,591,237	10,612,254	256,333	885,986
4.	Approval of Bionomics Ltd Employee Equity Plan	Carried unanimously on a show of hands	136,719,240	1,364,032	8,240,552	1,021,986

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+61 8 8354 6101
drathjen@bionomics.com.au

Mr Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6181
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic

acetylcholine receptor. The Company is also developing BNC101, its lead humanised monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au